The Canadian drugmaker on Wednesday announced to add three new directors to its board. Representative from Pershing Square Capital Management was added as one of the directors.
Bausch & Lomb
Breaking News
Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it plans to buy rights to a new schizophrenia treatment from Merck & Co and cut annual operating costs by $500 million in fiscal 2016.
